SEARCH

SEARCH BY CITATION

References

  • Atkins MB, Lotze MT, Dutcher JP et al. (1999): High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 21052116.
  • Bar-Eli M (1999): Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67: 1218.
  • Bartlema YM, Oosterhuis JA, Journee-De Korver JG, Tjho-Heslinga RE & Keunen JE (2003): Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol 87: 13701373.
  • Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F & Varinli S (2005): Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 13: 375381.
  • Char DH, Kroll S, Phillips TL & Quivey JM (2002): Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 109: 18501854.
  • Collaborative Ocular Melanoma Study Group. (2006): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 124: 16841693.
  • Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M & Parmiani G (1992): Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 2: 181189.
  • Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS & Burnier MN Jr (2004): Secretion of interleukin-6 and prostaglandin E2 during uveal melanoma-monocyte in vitro interactions. Exp Eye Res 79: 451454.
  • Damato B, Patel I, Campbell IR, Mayles HM & Errington RD (2005): Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 63: 385391.
  • Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A & Howard P (2007): Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114: 19251931.
  • Elgert KD, Alleva DG & Mullins DW (1998): Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275290.
  • Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M & Ochiai A (2009): Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125: 12761284.
  • Hallermalm K, Seki K, De Geer A et al. (2008): Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180: 37663774.
  • Hanahan D & Weinberg RA (2000): The hallmarks of cancer. Cell 100: 5770.
  • Ijland SA, Jager MJ, Heijdra BM, Westphal JR & Peek R (1999): Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 9: 445450.
  • Katerinaki E, Evans GS, Lorigan PC & MacNeil S (2003): TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer 89: 11231129.
  • Kawano M, Hirano T, Matsuda T et al. (1988): Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 8385.
  • Koga M, Kai H, Egami K et al. (2008): Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 365: 279284.
  • Kujala E, Makitie T & Kivela T (2003): Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 46514659.
  • Kvanta A, Steen B & Seregard S (1996): Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 63: 511518.
  • Lee CS, Lee J, Choi JJ, Yang WI, Yoon JS, Lee SY & Lee SC (2011): Cytogenetics and prognosis for uveal melanoma in Korean patients. Acta Ophthalmol 89: e310e314.
  • Lejeune FJ, Ruegg C & Lienard D (1998): Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10: 573580.
  • Li A, Dubey S, Varney ML, Dave BJ & Singh RK (2003): IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 33693376.
  • Likhvantseva VG, Slepova OS & Brovkina AF (1999): [Interferon status of patients with uveal melanoma]. Vestn oftalmol 115: 3537.
  • Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, Luyten GP & Jager MJ (2010): Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 51: 54455451.
  • Makitie T, Summanen P, Tarkkanen A & Kivela T (2001): Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 14141421.
  • Martin D, Galisteo R & Gutkind JS (2009): CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284: 60386042.
  • Meeren AV, Bertho JM, Vandamme M & Gaugler MH (1997): Ionizing radiation enhances IL-6 and IL-8 production by human endothelial cells. Mediators Inflamm 6: 185193.
  • Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE & Jager MJ (2006): Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 124: 14281434.
  • Molloy RM, Mc Connell RI, Lamont JV & FitzGerald SP (2005): Automation of biochip array technology for quality results. Clin Chem Lab Med 43: 13031313.
  • Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM & Bleeker JC (1995): Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 113: 315321.
  • Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH & Becher R (1996): Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 12221225.
  • Puusaari I, Heikkonen J & Kivela T (2004): Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 111: 17681777.
  • Sheidow TG, Hooper PL, Crukley C, Young J & Heathcote JG (2000): Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 84: 750756.
  • Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M & Brady LW (2002): Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 120: 933940.
  • Toivonen P & Kivela T (2010): Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma. Acta Ophthalmol. [Epub ahead of print].
  • Whitcup SM, Stark-Vancs V, Wittes RE, Solomon D, Podgor MJ, Nussenblatt RB & Chan CC (1997): Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 115: 11571160.
  • Yang W, Chen PW, Li H, Alizadeh H & Niederkorn JY (2008): PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 49: 25182525.